Study Results
Results pending
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
Recruitment Status
COMPLETED
Total Enrollment
156 participants
Study Classification
OBSERVATIONAL
Study Start Date
2003-02-20
Study Completion Date
2022-12-16
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Background:
* Breast cancer is the most common malignancy in women, occurring in over 230,000 women annually in the United States.
* The vast majority of breast cancers originate in the single layer of epithelial cells that line the ductal/lobular system of the breast milk ducts. The premalignant changes which occur in the transformed epithelium are not well understood, however several cytologic or histologic changes have been identified which are associated with an increased risk for breast cancer, including ductal or lobular hyperplasia, hyperplasia with atypia, and lobular or ductal carcinoma in situ.
* The identification of cytological or histological abnormalities in breast epithelial cells is an important component of risk assessment.
Objective:
Primary objectives are:
* To determine the incidence and nature of cytologic changes in ductal epithelial cells from the high-risk breast, in specimens collected by breast ductal lavage, and to determine if these cytologic findings are different from those of female normal volunteers not at increased risk for breast cancer.
* To characterize by breast duct endoscopy, high risk breast ductal epithelium and architecture, and correlate these findings with the cytologic findings referenced in above bullet.
* To determine what is the global gene expression pattern of high risk breast epithelial cells from the high risk breast, and does this differ from that of breast epithelial cells from female normal volunteersnot at increased risk for breast cancer. The gene expression profile will be determined by cDNA microarray and validated by RT-PCR.
Eligibility:
Eligibility for high risk individuals will include:
* Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
* Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women known to be BRCA1/2 or other hereditary genes mutation carriers.
* Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ.
* Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
* Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/ml, and a serum estradiol level of less than40 pg/ml to document postmenopausal status.
Eligibility for normal volunteers will include:
* Women who are premenopausal or postmenopausal with a Gail model risk index less than 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and racematched general population risk.
* Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \>40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age by mammogram. There must be no history of atypical hyperplasia, invasive or in situ carcinoma.
Both groups must have acceptable white blood cell and platelet counts.
Design:
Breast ductal epithelial cells will be collected by breast ductal lavage from (a) the breast in women at increased risk for breast cancer, and (b) the breast of female normal volunteers who are not at increased risk for breast cancer.
Ductal epithelial cell specimens will be analyzed cytologically for the presence of hyperplasia, atypia, or in situ changes.
Breast duct endoscopy will be performed in breast cancer patients and in normal volunteers with cytologic atypia on ductal lavage to determine ductal architectural changes associated with increased risk for breast cancer, and to provide correlation with cytologic atypia.
The gene expression profile of normal and high-risk ductal epithelial cells will be studied by cDNA-microarray to determine changes in gene expression associated with increased risk for breast cancer.
Additional molecular profiling experiments which will be performed as lavage cells are available include DNA whole exome sequencing, Comparative Genomic Hybridization (CGH), proteomic tissue lysate arrays, and identification of mammary stem cells.
A total of 104 high-risk subjects and 110 normal volunteers will be studied, divided approximately evenly between premenopausal and postmenopausal women....
* Breast cancer is the most common malignancy in women, occurring in over 230,000 women annually in the United States.
* The vast majority of breast cancers originate in the single layer of epithelial cells that line the ductal/lobular system of the breast milk ducts. The premalignant changes which occur in the transformed epithelium are not well understood, however several cytologic or histologic changes have been identified which are associated with an increased risk for breast cancer, including ductal or lobular hyperplasia, hyperplasia with atypia, and lobular or ductal carcinoma in situ.
* The identification of cytological or histological abnormalities in breast epithelial cells is an important component of risk assessment.
Objective:
Primary objectives are:
* To determine the incidence and nature of cytologic changes in ductal epithelial cells from the high-risk breast, in specimens collected by breast ductal lavage, and to determine if these cytologic findings are different from those of female normal volunteers not at increased risk for breast cancer.
* To characterize by breast duct endoscopy, high risk breast ductal epithelium and architecture, and correlate these findings with the cytologic findings referenced in above bullet.
* To determine what is the global gene expression pattern of high risk breast epithelial cells from the high risk breast, and does this differ from that of breast epithelial cells from female normal volunteersnot at increased risk for breast cancer. The gene expression profile will be determined by cDNA microarray and validated by RT-PCR.
Eligibility:
Eligibility for high risk individuals will include:
* Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
* Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women known to be BRCA1/2 or other hereditary genes mutation carriers.
* Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ.
* Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
* Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/ml, and a serum estradiol level of less than40 pg/ml to document postmenopausal status.
Eligibility for normal volunteers will include:
* Women who are premenopausal or postmenopausal with a Gail model risk index less than 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and racematched general population risk.
* Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \>40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age by mammogram. There must be no history of atypical hyperplasia, invasive or in situ carcinoma.
Both groups must have acceptable white blood cell and platelet counts.
Design:
Breast ductal epithelial cells will be collected by breast ductal lavage from (a) the breast in women at increased risk for breast cancer, and (b) the breast of female normal volunteers who are not at increased risk for breast cancer.
Ductal epithelial cell specimens will be analyzed cytologically for the presence of hyperplasia, atypia, or in situ changes.
Breast duct endoscopy will be performed in breast cancer patients and in normal volunteers with cytologic atypia on ductal lavage to determine ductal architectural changes associated with increased risk for breast cancer, and to provide correlation with cytologic atypia.
The gene expression profile of normal and high-risk ductal epithelial cells will be studied by cDNA-microarray to determine changes in gene expression associated with increased risk for breast cancer.
Additional molecular profiling experiments which will be performed as lavage cells are available include DNA whole exome sequencing, Comparative Genomic Hybridization (CGH), proteomic tissue lysate arrays, and identification of mammary stem cells.
A total of 104 high-risk subjects and 110 normal volunteers will be studied, divided approximately evenly between premenopausal and postmenopausal women....
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Cell Lines From High-Risk Breast Tissue
NCT00032201
Healthy
COMPLETED
Establishment of Normal Breast Epithelial Cell Lines From Patients at High Risk for Breast Cancer
NCT00001496
Breast Neoplasm
Hereditary Neoplastic Syndrome
COMPLETED
Studying Normal Breast Tissue and Cancer Risk
NCT00341692
Breast Neoplasms
Neoplasms by Site
Neoplasms
+2 more
COMPLETED
Identification of Biomarkers in Women at High Risk or Average Risk of Breast Cancer
NCT00897416
Breast Cancer
COMPLETED
Studying Tissue Samples From Women With Breast Cancer Who Were Treated on Clinical Trial NCCTG-N9831
NCT00898898
Breast Cancer
COMPLETED
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Background:
Breast cancer is the most common malignancy in women, occurring in over 230,000 women annually in the United States.
The vast majority of breast cancers originate in the single layer of epithelial cells that line the ductal/lobular system of the breast milk ducts. The premalignant changes which occur in the transformed epithelium are not well understood: however, several cytologic or histologic changes have been identified which are associated with an increased risk for breast cancer, including ductal or lobular hyperplasia, hyperplasia with atypia, and lobular or ductal carcinoma in situ.
The identification of cytological or histological abnormalities in breast epithelial cells is an important component of risk assessment.
Objective:
Primary objectives:
To determine the incidence and nature of cytologic changes in ductal epithelial cells from the high-risk breast, in specimens collected by breast ductal lavage, and to determine if these cytologic findings are different from those of female normal volunteers not at increased risk for breast cancer.
To characterize by breast duct endoscopy high-risk breast ductal epithelium and architecture, and correlate these findings with the cytologic findings referenced in above bullet.
To determine what is the global gene expression pattern of high-risk breast epithelial cells from the high-risk breast, and does this differ from that of breast epithelial cells from female normal volunteers not at increased risk for breast cancer. The gene expression profile will be determined by cDNA microarray and validated by RT-PCR.
Eligibility:
Eligibility for high-risk individuals will include:
Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
Women without breast cancer, but with a Gail Index \> 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
Women known to be BRCA1/2 or other hereditary genes mutation carriers.
Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ.
Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/mL, and a serum estradiol level of \< 40 pg/mL to document postmenopausal status.
Eligibility for normal volunteers will include:
Women who are premenopausal or postmenopausal with a Gail model risk index \< 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/mL, and a serum estradiol level of \< 40 pg/mL to document postmenopausal status.
Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age, by mammogram. There must be no history of atypical hyperplasia, invasive, or in situ carcinoma.
Both groups must have acceptable white blood cell and platelet counts.
Design:
Breast ductal epithelial cells will be collected by breast ductal lavage from (a) the breast in women at increased risk for breast cancer, and (b) the breast of female normal volunteers who are not at increased risk for breast cancer.
Ductal epithelial cell specimens will be analyzed cytologically for the presence of hyperplasia, atypia, or in situ changes.
Breast duct endoscopy will be performed in breast cancer patients and in normal volunteers with cytologic atypia on ductal lavage to determine ductal architectural changes associated with increased risk for breast cancer, and to provide correlation with cytologic atypia.
The gene expression profile of normal and high-risk ductal epithelial cells will be studied by cDNA microarray to determine changes in gene expression associated with increased risk for breast cancer.
Additional molecular profiling experiments which will be performed as lavage cells are available include DNA whole exome sequencing, comparative genomic hybridization (CGH), proteomic tissue lysate arrays, and identification of mammary stem cells.
A total of 104 high-risk subjects and 110 normal volunteers will be studied, divided approximately evenly between premenopausal and postmenopausal women.
Breast cancer is the most common malignancy in women, occurring in over 230,000 women annually in the United States.
The vast majority of breast cancers originate in the single layer of epithelial cells that line the ductal/lobular system of the breast milk ducts. The premalignant changes which occur in the transformed epithelium are not well understood: however, several cytologic or histologic changes have been identified which are associated with an increased risk for breast cancer, including ductal or lobular hyperplasia, hyperplasia with atypia, and lobular or ductal carcinoma in situ.
The identification of cytological or histological abnormalities in breast epithelial cells is an important component of risk assessment.
Objective:
Primary objectives:
To determine the incidence and nature of cytologic changes in ductal epithelial cells from the high-risk breast, in specimens collected by breast ductal lavage, and to determine if these cytologic findings are different from those of female normal volunteers not at increased risk for breast cancer.
To characterize by breast duct endoscopy high-risk breast ductal epithelium and architecture, and correlate these findings with the cytologic findings referenced in above bullet.
To determine what is the global gene expression pattern of high-risk breast epithelial cells from the high-risk breast, and does this differ from that of breast epithelial cells from female normal volunteers not at increased risk for breast cancer. The gene expression profile will be determined by cDNA microarray and validated by RT-PCR.
Eligibility:
Eligibility for high-risk individuals will include:
Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
Women without breast cancer, but with a Gail Index \> 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
Women known to be BRCA1/2 or other hereditary genes mutation carriers.
Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or lobular carcinoma in situ.
Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/mL, and a serum estradiol level of \< 40 pg/mL to document postmenopausal status.
Eligibility for normal volunteers will include:
Women who are premenopausal or postmenopausal with a Gail model risk index \< 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of \> 40 IU/mL, and a serum estradiol level of \< 40 pg/mL to document postmenopausal status.
Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age, by mammogram. There must be no history of atypical hyperplasia, invasive, or in situ carcinoma.
Both groups must have acceptable white blood cell and platelet counts.
Design:
Breast ductal epithelial cells will be collected by breast ductal lavage from (a) the breast in women at increased risk for breast cancer, and (b) the breast of female normal volunteers who are not at increased risk for breast cancer.
Ductal epithelial cell specimens will be analyzed cytologically for the presence of hyperplasia, atypia, or in situ changes.
Breast duct endoscopy will be performed in breast cancer patients and in normal volunteers with cytologic atypia on ductal lavage to determine ductal architectural changes associated with increased risk for breast cancer, and to provide correlation with cytologic atypia.
The gene expression profile of normal and high-risk ductal epithelial cells will be studied by cDNA microarray to determine changes in gene expression associated with increased risk for breast cancer.
Additional molecular profiling experiments which will be performed as lavage cells are available include DNA whole exome sequencing, comparative genomic hybridization (CGH), proteomic tissue lysate arrays, and identification of mammary stem cells.
A total of 104 high-risk subjects and 110 normal volunteers will be studied, divided approximately evenly between premenopausal and postmenopausal women.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Breast Cancer
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
Observational Model Type
COHORT
Study Time Perspective
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
1/Breast Cancer and High-Risk Patients
Pre- or postmenopausal women who have or have previously had invasive or noninvasive breast cancer of epithelial origin, or women without breast cancer but at an increased risk of breast cancer.
No interventions assigned to this group
2/Normal Volunteers
Pre- or postmenopausal women who are not at an increased risk for breast cancer.
No interventions assigned to this group
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Age greater than or equal to 18 years and less than or equal to 74 years.
* Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
* Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women known to be BRCA1/2 or other hereditary genes mutation carriers.
* Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or LCISl
* Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
* Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Breast cancer may be invasive or noninvasive, and in the past or the present.
* The contralateral breast of women with breast cancer, or the normal breast of high-risk subjects, must be free of any suspicious areas by physical examination and mammogram, and without a history of invasive ductal or in situ ductal carcinoma. History of atypia or LCIS on a previous biopsy is acceptable.
* Women who are from a family with heritable breast cancer with a known deleterious BRCA1/2 or other hereditary genes mutation, who themselves have been tested and to not carry this mutation. These women are not at increased risk for breast cancer due to the familial mutation and are eligible to participate as normal volunteers.
* WBC greater than 2,500.
* Platelets greater than 50,000.
* Age greater than or equal to 18 years and less than or equal to 74 years.
* Women who are premenopausal or postmenopausal with a Gail model risk index less than 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age by mammogram. There must be no history of atypical hyperplasia, invasive or in situ carcinoma.
* WBC greater than 2,500.
* Platelets greater than 50,000.
* Women with a unilateral invasive or noninvasive (DCIS) breast cancer of epithelial origin.
* Women without breast cancer, but with a Gail Index greater than 1.67 percent, or a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women known to be BRCA1/2 or other hereditary genes mutation carriers.
* Women with cytologic or histologic evidence of ductal hyperplasia, atypical ductal hyperplasia, or LCISl
* Women may be either premenopausal or postmenopausal. Postmenopausal is defined by the absence of menstrual periods for at least 12 months.
* Postmenopausal women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Breast cancer may be invasive or noninvasive, and in the past or the present.
* The contralateral breast of women with breast cancer, or the normal breast of high-risk subjects, must be free of any suspicious areas by physical examination and mammogram, and without a history of invasive ductal or in situ ductal carcinoma. History of atypia or LCIS on a previous biopsy is acceptable.
* Women who are from a family with heritable breast cancer with a known deleterious BRCA1/2 or other hereditary genes mutation, who themselves have been tested and to not carry this mutation. These women are not at increased risk for breast cancer due to the familial mutation and are eligible to participate as normal volunteers.
* WBC greater than 2,500.
* Platelets greater than 50,000.
* Age greater than or equal to 18 years and less than or equal to 74 years.
* Women who are premenopausal or postmenopausal with a Gail model risk index less than 1.67 percent, and without a cumulative lifetime risk greater than or equal to double the age- and race-matched general population risk.
* Women who have previously undergone a hysterectomy without oophorectomy must have a serum FSH level of greater than 40 IU/ml, and a serum estradiol level of less than 40 pg/ml to document postmenopausal status.
* Both breasts must be free of any suspicious areas by physical examination and, for women over 30 years of age by mammogram. There must be no history of atypical hyperplasia, invasive or in situ carcinoma.
* WBC greater than 2,500.
* Platelets greater than 50,000.
Exclusion Criteria
* Contralateral breast prosthesis
* Pregnancy
* History of radiation therapy to the contralateral breast
* Lactating breasts
* Chemotherapy within the past 1 month
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous contralateral major duct excision
* Bilateral breast prosthesis
* Pregnancy
* Lactating breasts
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous bilateral major duct excision
* History of therapeutic mediastinal radiation
* Bilateral breast prosthesis
* Pregnancy
* Lactating breasts
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous bilateral major duct excision
* History of therapeutic mediastinal radiation
* Pregnancy
* History of radiation therapy to the contralateral breast
* Lactating breasts
* Chemotherapy within the past 1 month
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous contralateral major duct excision
* Bilateral breast prosthesis
* Pregnancy
* Lactating breasts
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous bilateral major duct excision
* History of therapeutic mediastinal radiation
* Bilateral breast prosthesis
* Pregnancy
* Lactating breasts
* Current antiestrogen therapy
* Current hormonal replacement therapy or oral contraceptives
* Concurrent infection
* Previous bilateral major duct excision
* History of therapeutic mediastinal radiation
Minimum Eligible Age
18 Years
Maximum Eligible Age
74 Years
Eligible Sex
FEMALE
Accepts Healthy Volunteers
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
National Cancer Institute (NCI)
NIH
Sponsor Role
lead
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Responsibility Role
SPONSOR
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
David N Danforth, M.D.
Role: PRINCIPAL_INVESTIGATOR
National Cancer Institute (NCI)
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
National Institutes of Health Clinical Center
Bethesda, Maryland, United States
Site Status
Countries
Review the countries where the study has at least one active or historical site.
United States
References
Explore related publications, articles, or registry entries linked to this study.
Fisher B, Costantino J, Redmond C, Fisher E, Margolese R, Dimitrov N, Wolmark N, Wickerham DL, Deutsch M, Ore L, et al. Lumpectomy compared with lumpectomy and radiation therapy for the treatment of intraductal breast cancer. N Engl J Med. 1993 Jun 3;328(22):1581-6. doi: 10.1056/NEJM199306033282201.
Reference Type
BACKGROUND
Greenlee RT, Murray T, Bolden S, Wingo PA. Cancer statistics, 2000. CA Cancer J Clin. 2000 Jan-Feb;50(1):7-33. doi: 10.3322/canjclin.50.1.7.
Reference Type
BACKGROUND
Fisher B, Dignam J, Wolmark N, Wickerham DL, Fisher ER, Mamounas E, Smith R, Begovic M, Dimitrov NV, Margolese RG, Kardinal CG, Kavanah MT, Fehrenbacher L, Oishi RH. Tamoxifen in treatment of intraductal breast cancer: National Surgical Adjuvant Breast and Bowel Project B-24 randomised controlled trial. Lancet. 1999 Jun 12;353(9169):1993-2000. doi: 10.1016/S0140-6736(99)05036-9.
Reference Type
BACKGROUND
Danforth DN, Filie AC, Warner AC, Wright GW, Sun Z, Ried T, McGowan CT, Prindiville SA. Characteristics of Breast Ducts in Normal-Risk and High-risk Women and Their Relationship to Ductal Cytologic Atypia. Cancer Prev Res (Phila). 2020 Dec;13(12):1027-1036. doi: 10.1158/1940-6207.CAPR-19-0305. Epub 2020 Aug 4.
Reference Type
DERIVED
Related Links
Access external resources that provide additional context or updates about the study.
https://clinicalstudies.info.nih.gov/cgi/detail.cgi?B_2002-C-0077.html
NIH Clinical Center Detailed Web Page
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
02-C-0077
Identifier Type: -
Identifier Source: secondary_id
020077
Identifier Type: -
Identifier Source: org_study_id
NCT00070460
Identifier Type: -
Identifier Source: nct_alias
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.
MRI and Gene Expression in Diagnosing Patients With Ductal Breast Cancer In Situ
NCT02352883
ACTIVE_NOT_RECRUITING
NA
Diagnostic Procedures in Detecting Tumor Cells in the Bone Marrow of Patients Undergoing Surgery for Stage I, Stage II, or Stage IIIA Breast Cancer
NCT00089323
COMPLETED
NA
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Annual Follow-Up Study
NCT00006421
COMPLETED
Biomarkers for Breast Cancer Risk in African American Women
NCT01736306
COMPLETED
High Risk Breast Clinic: Protocol for Women at Increased Risk for Developing Breast Cancer
NCT00291096
RECRUITING
Clinical, Genetic, Behavioral, Laboratory and Epidemiologic Characterization of Individuals and Families at High Risk of Breast/Ovarian Cancer
NCT00040222
COMPLETED
The Breast Duct: Pilot Study of Genomic Sequencing of Exfoliated Ductal Cells Obtained Through Endoscopy and Lavage
NCT02121873
COMPLETED
Duct Endoscopy in Assessing Cellular Atypia in the Breast Duct Fluid of Women With a Genetic Risk for Breast Cancer
NCT00082979
UNKNOWN
PHASE2
Study of Breast Tissue in Women Not Previously Diagnosed With Breast Cancer Who Are Undergoing Fine Needle Aspiration
NCT00896636
UNKNOWN
Breast Stem Cells in Women at Average Risk and Increased Risk for Breast Cancer
NCT00923377
COMPLETED
Genetic and Protein Profiling in Normal and Cancerous Breast Tissue
NCT00083733
COMPLETED
Breast Cancer Risk in Women Who Are BRCA1/BRCA2 Mutation Carriers
NCT00899145
WITHDRAWN
Studying Blood and Tumor Tissue Samples in Women With Invasive Breast Cancer, Ductal or Lobular Carcinoma in Situ, or Benign Breast Disease
NCT00898508
COMPLETED
Nipple Aspiration, Ductal Lavage, and Duct Endoscopy in Screening Women at Moderate-to-High Risk of Developing Breast Cancer
NCT00081003
COMPLETED
NA
Breast Imaging Studies in Women at High Genetic Risk of Breast Cancer: Menstrual Cycle Study
NCT00006425
COMPLETED
Study of Ductal Lavage in Women at High Risk for Breast Cancer
NCT00429988
COMPLETED
Epigenetic Testing for Breast Cancer Risk Stratification
NCT01501656
COMPLETED
Isolation and Characterization of Mammary Stem Cells
NCT00340392
COMPLETED
Markers for Breast Cancer
NCT00339248
COMPLETED
Protocol to Examine Methylation of Tumor Suppression Genes in Women at High Risk of Developing Breast Cancer
NCT00323908
COMPLETED
Rapid Histologic Assessment for Stereotactic Breast Biopsy: Enhancing Early Detection With Miniature Mass Spectrometry and AI
NCT06663228
RECRUITING
Transformation Potential of E2 Exposed Breast Cancer Susceptibility Gene Mutation Heterozygous Epithelial Breast Cells
NCT01907438
UNKNOWN
Comprehensive Screening for Women at High Genetic Risk for Developing Breast Cancer
NCT00255060
COMPLETED